Schizophrenia Bulletin
-
Publication Venue For
- Mental Health and Functional Outcomes in Young Adulthood of Children With Psychotic Symptoms: A Longitudinal Cohort Study. 2019
- Effects of Schizophrenia Polygenic Risk Scores on Brain Activity and Performance During Working Memory Subprocesses in Healthy Young Adults.. 44:844-853. 2018
- Cumulative Effects of Neighborhood Social Adversity and Personal Crime Victimization on Adolescent Psychotic Experiences.. 44:348-358. 2018
- Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia. 42:425-433. 2016
- A meta-analysis of mentalizing impairments in adults with schizophrenia and autism spectrum disorder.. 40:602-616. 2014
- The effect of context processing on different aspects of social cognition in schizophrenia.. 37:1048-1056. 2011
- 3-HYDROXYKYNURENINE AND COGNITIVE IMPAIRMENT IN FIRST-EPISODE NEUROLEPTIC-NAIVE PATIENTS WITH SCHIZOPHRENIA. 35:151-151. 2009
- Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.. 35:336-346. 2009
- EFFICACY AND TOLERABILITY OF ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH SCHIZOPHRENIA. 35:356-357. 2009
- NEUROSTEROIDS AS NOVEL THERAPEUTIC AGENTS IN SCHIZOPHRENIA AND PTSD. 35:368-368. 2009
- Voxel-based morphometric multisite collaborative study on schizophrenia.. 35:82-95. 2009
- fMRI activity correlated with auditory hallucinations during performance of a working memory task: data from the FBIRN consortium study.. 35:47-57. 2009
- Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.. 34:656-663. 2008
- How should DSM-V criteria for schizophrenia include cognitive impairment?. 33:912-920. 2007
- A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.. 31:5-19. 2005
- Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.. 30:3-20. 2004
- Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia.. 30:587-598. 2004
- Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates.. 30:45-57. 2004
- Revised PORT recommendations.. 30:609-611. 2004
- The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.. 30:577-586. 2004
- Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.. 29:33-43. 2003
- Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.. 29:45-55. 2003
- The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.. 29:15-31. 2003
- Concealed medicines for people with schizophrenia: a U.S. perspective.. 28:537-542. 2002
- Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia.. 27:697-708. 2001
- The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.. 25:201-222. 1999
- Common sense, insight, and neuropsychological test performance in schizophrenia patients.. 22:635-641. 1996
- Characteristic hostility in schizophrenic outpatients.. 17:163-171. 1991
- Animal models for schizophrenia: the hippocampally lesioned animal.. 13:317-327. 1987
- CLINICAL AND FUNCTIONAL OUTCOMES IN YOUNG ADULTHOOD OF CHILDREN WITH PSYCHOTIC SYMPTOMS: A LONGITUDINAL TWIN COHORT STUDY 2018
- EPIGENETIC SIGNATURES OF CHILDHOOD AND ADOLESCENT VICTIMISATION USING A GENETICALLY SENSITIVE LONGITUDINAL COHORT STUDY 2018
- PROTECTIVE FACTORS FOR PSYCHOTIC EXPERIENCES AMONGST ADOLESCENTS EXPOSED TO MULTIPLE FORMS OF VICTIMIZATION 2018
- FINDING THE SITES OF GLUTAMATE CIRCUITRY ABNORMALITY IN SCHIZOPHRENIA WITH PROTON MRS 2015
- GABA AND GLUTAMATE DYSFUNCTION IN SCHIZOPHRENIA: DISTINGUISHING MEDICATION EFFECTS FROM NEUROBIOLOGY 2015
- SLEEP PATTERNS OF INDIVIDUALS WITH SCHIZOPHRENIA 2011
- Clozapine increases the neurosteroid pregnenolone in rat hippocampus, cerebral cortex, and serum: Relevance to superior efficacy? 2007
- Pregnenolone reductions in parietal cortex are associated with suicide in patients with schizophrenia 2007
- Disrupted task related activation to action selection and conflict resolution in patients with schizophrenia 2005
- Neuroactive steroid alterations in schizophrenia and bipolar disorder: Negative ion chemical ionization gas chromatography/mass spectrometry investigations in posterior cingulate and parietal cortex 2005
- Neuropsychological deficits at age 13 and later schizophreniform disorder: A longitudinal birth cohort study 2005
- Olanzapine and fluoxetine effects on hippocampal pregnenolone and peripheral deoxycorticosterone: Relevance to therapeutic efficacy 2005